A Phase 1b/3 Global, Randomized, Double-blind, Placebo Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to learn about the effects, safety, and proper dosage of tazemetostat in combination with doxorubicin for the treatment of soft tissue sarcoma. Doxorubicin is a common therapy for soft tissue sarcoma, but is not FDA approved in combination with tazemetostat. This study treatment combination may suppress or prevent tumor growth by inhibiting certain enzymes.
This study is closed
Matthew Ingham, MD
|Are you aged 18 years or older?
|Do you have confirmed diagnosis of soft tissue sarcoma?
|Have you ever taken tazemetostat or other systemic cancer treatments?